Add-on spironolactone as antagonist of the NRG1-ERBB4 signaling pathway for the treatment of schizophrenia: Study design and methodology of a multicenter randomized, placebo-controlled trial

Autor: Hasan, Alkomiet, Roeh, Astrid, Leucht, Stefan, Langguth, Berthold, Hansbauer, Maximilian, Oviedo-Salcedo, Tatiana, Kirchner, Sophie K., Papazova, Irina, Löhrs, Lisa, Wagner, Elias, Maurus, Isabel, Strube, Wolfgang, Rossner, Moritz J., Wehr, Michael C., Bauer, Ingrid, Heres, Stephan, Leucht, Claudia, Kreuzer, Peter M., Zimmermann, Stephanie, Schneider-Axmann, Thomas, Görlitz, Thomas, Karch, Susanne, Egert-Schwender, Silvia, Schossow, Beate, Rothe, Philipp, Falkai, Peter
Zdroj: In Contemporary Clinical Trials Communications March 2020 17
Databáze: ScienceDirect